In keeping with the majority of previous studies that also evaluated the immunohistochemical detection of the BRAF V600E mutation in comparison to gold standard molecular testing in a variety of tumor types [16,18,20,26-34], we concluded that immunohistochemistry is an accurate detection method for the BRAF V600E mutation in PXA. The gene discussed is BRAF; the disease is neoplasm.